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ABSTRACT 
Introduction: 
Non-Hodgkin Lymphoma (NHL) constitutes a heterogeneous group of lymphoproliferative 
disorders with a variable clinical and biological spectrum. Diffuse large B-cell lymphoma 
(DLBCL) is the most common histological subtype of NHL and is the prototype of the 
aggressive lymphomas. DLBCL accounts for approximately one third of all newly diagnosed 
patients with NHL.  
Aim: 
The aim of the study was to review the demographic and clinical profile as well as the treatment 
and outcome of adult patients with DLBCL, at Chris Hani Baragwanath Academic Hospital 
(CHBAH). Furthermore, the study explored the impact of Human immunodeficiency virus 
(HIV) on the study population and compared the findings in both HIV seronegative and HIV 
seropositive patients, over a 5 year period (01/01/2008 to 31/12/2012). 
Methodology: 
This study entailed a retrospective review of all patients seen at CHBAH during the above time 
period, with a confirmed histological diagnosis of DLBCL. A data sheet was used to collect 
relevant information (demographics, clinical presentation, diagnostic tools, staging of the 
disease, prognostic factors and management) from the files of patients attending the Clinical 
Haematology unit, Department of Medicine, CHBAH. 
Results: 
A total of 139 evaluable patients were reviewed during the study period. The majority of 
patients were from the Gauteng province (83%), and of black African ethnicity (95%), in 
keeping with the patient demographics seen at CHBAH. There were 73 females (53%) and 66 
males (47%) males, with a female: male ratio of 1.1:1. The median age of the patients was 41 
years, with a range of 14-85 years.  
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Common presenting features included constitutional symptoms (76%), extranodal disease 
(73%) and lymphadenopathy (64%). Most patients presented with advanced stage (III and IV) 
disease (76%). 
Human immunodeficiency virus (HIV) infection had a major impact on the study population, 
with 81% of the patients being HIV seropositive. HIV seropositive patients presented at a 
younger age of 39 years and had a female to male ratio of 1.04:1. A direct comparison between 
HIV seropositive and HIV seronegative individuals was less meaningful in this study, in view 
of the small number of HIV seronegative patients. However, adverse prognostic factors were 
consistently noted in the HIV seropositive patients, similar to the entire cohort (i.e. all the 
patients). In addition, tuberculosis was a comorbidity that was more strongly associated with 
HIV seropositivity. 
The median overall survival for all the patients in the study was 24 months. This generally 
poorer survival is attributed to significant delays in diagnosis and subsequent late referrals, late 
presentations with more advanced stage disease, more ‘B’ symptoms, more extranodal disease 
as well as the significant impact of HIV on NHL.  
HIV seropositive patients present with more aggressive histological subtypes (however, this  
study was specific to DLBCL and limited to DLBCL), atypical clinical and laboratory features, 
more frequent comorbidities such as tuberculosis and other opportunistic infections, more 
myelosuppression, delays in giving chemotherapy on schedule, and ultimately, a poorer 
prognosis. 
Conclusion:  
NHL is the most common haematological malignancy encountered in adults at CHBAH. 
DLBCL accounts for 35% of all the patients with NHL. HIV seropositivity is present in 81% 
of the patients with DLBCL and has a significant impact with regard to the presentation and 
outcome of the patients in our study. More recently, with the early introduction and continuation 
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of combination antiretroviral treatment (cART), the institution of appropriate antibiotic and 
CNS prophylaxis, the more liberal use of growth factors and more optimal chemotherapy with 
the early introduction of etoposide and rituximab and the use of autologous stem cell 
transplantation in patients with relapsed, chemosensitive disease, it is hoped that the outcome 
of patients with DLBCL treated at CHBAH, will improve significantly compared to the 
outcome of the patients in this retrospective study. 
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CHAPTER 1 
1. INTRODUCTION AND LITERATURE REVIEW 
1.1. Definition and subtypes of Diffuse large B-cell Non-Hodgkin Lymphoma: 
Non-Hodgkin Lymphoma (NHL) constitutes a heterogeneous group of haematological 
malignancies with a variable biological and clinical spectrum. (1) Diffuse large B-cell 
lymphoma (DLBCL) is the most common histological subtype of NHL and is the prototype of 
the aggressive lymphomas. DLBCL accounts for approximately one third of all newly 
diagnosed patients with NHL. DLBCL is not a single entity, despite having a similar 
morphological appearance. (1,2) DLBCL is further characterized into i) Clinical subtypes such 
as DLBCL, not otherwise specified (NOS), ii) Morphological variants such as the centroblastic 
and immunoblastic variants, and iii) Molecular subtypes such as germinal centre B-cell-like 
(GCB) and activated B-cell-like (ABC) DLBCL. (1-5) The 2016 revision of the World Health 
Organization (WHO) classification of lymphoid neoplasms includes a number of changes from 
the 2008 classification, most notably now a distinct cell of origin classification of DLBCL, NOS 
into GCB and ABC types. (5)  
 
1.2. History of classification of DLBCL subtypes: 
In 1994, the revised European-American Lymphoma (REAL) classification was proposed by 
the International Lymphoma Study Group (ILSG), unifying these subtypes into a single group 
known as Diffuse Large B-cell Lymphoma (DLBCL).  The REAL group based their unification 
of the subtypes on ‘genetic studies, immunophenotyping, lymphoid lineage and an insight into 
lymphocyte studies’. The decision to unify these subtypes was further based on the fact that 
there was similarity of clinical behaviour and approach to the treatment of these subtypes. (6,7) 
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The World Health Organisation (WHO) supported the unification of the subtypes into one group 
of DLBCL in 2001. The classification by REAL and the WHO, further helped distinguish 
DLBCL from other forms of aggressive NHL, such as Peripheral T-cell Lymphoma, Mantle 
cell Lymphoma, Anaplastic large T-cell Lymphoma, Follicular large cell Lymphoma, Burkitt 
(BL) and Burkitt-like Lymphoma. (4) Prior to the REAL and WHO support for unification of 
the subtypes of NHL into DLBCL, there existed different descriptors of the disease entity based 
on the pathological classification (see Table 1.1). (7) 
 
Table 1.1: DLBCL in NHL pathologic classification system (7) 
Author Descriptor Year of Publication 
Rappaport 
(morphologic) 
Diffuse Histiocytic Lymphoma 1966 
Kiel 
(cell lineage and 
differentiation) 
Centroblastic Lymphoma, 
B-immunoblastic Lymphoma 
B-large cell Anaplastic Lymphoma 
1974 
Luke-Collins (cell 
lineage and 
differentiation) 
Large cleaved Follicular centre cell  
Lymphoma and 
B-immunoblastic Lymphoma 
1974 
Working Formulation 
(morphological and 
clinical prognosis) 
Diffuse mixed small and large cell 
Lymphoma (Group F) 
Diffuse large cell 
Lymphoma (Group G) 
Large cell immunoblastic Lymphoma 
(Group H) 
1982 
REAL and WHO 
(morphologic, 
immunophenotypic, 
genotypic and 
clinical) 
Diffuse large B-cell lymphoma 1994 and 2001 
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1.3. Sub-classification of Diffuse large B cell Lymphoma: 
DLBCL can be further subdivided into 3 different subgroups as indicated in the introduction.  
This subdivision is based on major sites of disease presentation, histological appearance and 
genetic expression (see Table 1.2). (3,8) 
 
Table 1.2: Subtypes of DLBCL according to molecular analysis (8) 
Expression profile similar to Germinal Centre B-cell type (GCB subtype) 
Mimicking the Activated Peripheral blood B-cell type (ABC subtype) 
Primary Mediastinal large B-cell Lymphoma (PMBCL) 
 
The significance of these subtypes is that they are associated with a variable prognosis and 
different survival rates. The GCB has better prognosis than ABC. The 5 year survival rate for 
the different subtypes is 59%, 30% and 64% (GCB, ABC and PMBCL, respectively). The 
PMBCL affects mediastinal lymph nodes. It also has some molecular similarity to Hodgkin 
lymphoma. (8) 
 
1.4. Epidemiology of DLBCL: 
Epidemiologically, DLBCL is the most common subtype of Non-Hodgkin Lymphoma (NHL), 
accounting for 30 to 40% of NHL worldwide, and 60-70% of the aggressive lymphomas of B-
cell origin. Approximately 30 000 new cases/annum of NHL are DLBCL. (2,7,9) 
The European incidence of DLBCL is 3-4/100 000 per year, increasing with increasing age 
(from 0.3/100 000 per year for 35-39 years of age, to 26.6/100 000 per year for 80-84 years of 
age). (10) In the United States (US), the disease incidence is >25 000 cases per annum or 
4.68/100 000 person-years. In general, the incidence has been increasing between 1973 and 
1991 and continues to increase. The increased incidence has contributed to increased mortality, 
despite advances in medical therapy. (11,12) 
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The median age of presentation of DLBCL is in the 6th decade of life (50 to 60 years). However, 
the age range is broad as the disease may also affect children. (9)  
The incidence of DLBCL in the US is increasing by 3 to 4% per year, across gender, all ages 
and races. The major contributory factors to this increase are: better and more sensitive 
diagnostic techniques, widespread use of iatrogenic immunosuppression and environmental 
factors such as HIV. (12,13) Other aetiological factors to be considered are environmental 
factors (e.g. ultraviolet (UV) radiation), dietary, genetic, chronic inflammatory 
diseases/autoimmune disease (e.g. Systemic lupus erythematosus (SLE), Rheumatoid arthritis 
(RA), Sjogren’s syndrome and Celiac disease) and occupational factors (farming, such as where 
there is exposure to pesticides) and recurrent exposure to hair dyes. (1,14,15) 
In the US, the incidence has been found to be higher in whites than blacks, in particular with 
regard to male gender. White American males were found to be 49% more at risk than their 
black counterparts. They were also found to be more at risk than Japanese American males by 
54% and 27% more than Chinese American males, respectively. (11)  
In general, in the US studies, there was a male to female preponderance of 1.3:1. The situation 
is different in South African studies with a younger age at presentation (mean age of 43 years 
and 42 years, respectively) and male to female ratio of 1.35:1 and 1.1:1respectively. (11,13)  
 
1.5. Pathophysiology of DLBCL: 
The pathogenesis of DLBCL can be understood by first looking at the normal pathway of B-
cell maturation. B-cells are released from the bone marrow. They migrate to lymphoid tissues, 
in particular, the lymph nodes. In the lymph nodes, the B-cells pass through the germinal 
centers. Somatic hypermutation (SHM) of the immunoglobulin variable region (IgV) takes 
place in the lymph node. Breakage of the deoxyribonucleic acid (DNA) is required for this 
process to occur. Somatic hypermutation (SHM) is necessary for the diversification and 
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increased antigen affinity, in the function of B-cells. It is also at this stage, in the germinal 
centre, that genetic aberrations like gene translocations and mutagenesis can occur. (14,15) 
The gene dysregulations that occur at this stage of B-cell maturation are in relation to the (B-
cell lymphoma) BCL6, BCL2 and cMYC genes. The BCL6 gene dysregulation is the 
commonest occurring in 35%-40%. The BCL6 gene is located at the 3q27 band on chromosome 
3. Therefore, the translocation that occurs on the 3q27 band results in abnormal proliferation of 
B-cells. The BCL6 chromosomal translocation can occur de novo. (14,15) BCL2 is a proto-
oncogene located on chromosome18q21. The translocation is commonly at the t (14;18) 
position on the gene, and accounts for 15% of DLBCL. The BCL2 gene regulates the balance 
between pro-apoptosis and anti-apoptosis of the B-cell, by the development of heterodimers 
and homodimers. The process and balance is necessary for B- cells that need to be destroyed 
and those that need to reach maturation. The development of more heterodimers over 
homodimers, due to gene dysregulation, favours anti-apoptosis. Hence, over-expression of the 
BCL2 gene is associated with inhibition of apoptosis, contributing to the development of 
DLBCL in some patients and classically to the development of follicular lymphoma. The 
presence of BCL2 has also been shown to confer chemotherapy resistance. (14,15) Over-
expression of cMYC is associated with the translocation t (8:14). This is found mostly in other 
aggressive forms of NHL, such as Burkitt lymphoma and an intermediate between DLBCL and 
Burkitt lymphoma (now referred to as High grade B-cell lymphoma, NOS. (5,15) The 
translocation t (8:14) occurs in 15% of DLBCL. (14,15) Other possible gene dysregulations in 
the formation of DLBCL are FAS (CD95), p53, aberrant SHM, and cREL. (14,15) 
Apoptosis stimulating fragment (FAS) mutations contribute to about 20% of DLBCL. They are 
proapoptotic proteins. They result in negative B-cell selection during maturation in the germinal 
centre of the lymphoid tissue. The other gene dysregulations (aberrant SHM, p53,     t (3:14) 
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chromosomal imbalances and cREL gene) make up 10-25% of the remaining DLBCL 
dysregulations. (14,15) 
Most DLBCL arise from lymphoid tissues as a primary disease (de novo). A few arise from 
other indolent forms of lymphoma (e.g. follicular lymphoma). This is known as secondary or 
transformed DLBCL. (7,14) 
All the mutations, translocations and amplifications affecting the regulatory genes in DLBCL, 
can also affect DLBCL subsets affecting the Central Nervous System (CNS), skin and T-cell 
rich B-cell lymphoma. (14) 
 
1.6. Clinical presentation of DLBCL: 
1.6.1. Nodal disease: 
Clinically, patients with DLBCL typically present with a rapidly growing mass, which may be 
nodal (lymphadenopathy) or extranodal. The nodal sites may be localized or generalized, central 
or peripheral. They are more common than extranodal sites. However, extranodal presentations 
is on the increase, and approximately one third of patients with NHL now present with 
extranodal disease. (16) The lymphadenopathy is often painless, but may be painful in rapidly 
enlarging nodes. The consistency of the lymph nodes is often described as firm-rubbery. (16,17) 
The common sites of lymphadenopathy include the cervical, axillary, inguinal/femoral regions. 
Lymphoedema can occur as a result of lymphatic obstruction. Lymphadenopathy that occurs in 
concealed areas such as the chest, may result in local symptoms. Cough and shortness of breath 
are some of the symptoms that may occur as a result of intrathoracic lymphadenopathy. (17,18)  
Obstructive jaundice complicates 1-2% of patients with NHL. It may occur as a complication 
of primary liver involvement by NHL, or metastatic disease to the liver or biliary tract. (19,20) 
Lymphadenopathy in the porta hepatis may also manifest as obstructive jaundice. (19)  
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When evaluating a patient with lymphadenopathy, a number of causes need to be considered. 
These include viral, bacterial, parasitic and fungal infections. Other causes that need to be 
excluded are autoimmune diseases such as RA and SLE, granulomatous disorders such as 
tuberculosis and sarcoidosis and drug related adenopathy (e.g. epanutin). However, when 
considering malignancies, and more particularly in the context of HIV seropositivity, 
lymphoma must always be considered and excluded (see Figure 1.1). (21) 
 
Figure 1.1: Distribution of different types of lesions on lymph node biopsy. 
HL = Non-Hodgkin lymphoma, FH = Follicular hyperplasia, SH = Sinus histiocytosis, PH = 
Paracortical hyperplasia, TB = Tuberculosis. (Adopted from Indian Journal of Pathology and 
Microbiology) (21) 
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1.6.2. Extranodal disease: 
Extranodal sites are affected in 30-40% of patients (i.e. approximately one third of patients). 
The affected sites are commonly the gastrointestinal tract (GIT) with the stomach being the 
most common site involved, central nervous system (CNS), skin, testes, bone, liver, spleen, 
breast and the kidney. The symptoms that occur with involvement of these sites are usually 
localized.  
The stomach involvement may present with gastritis, gastric outlet obstruction or gastric 
bleeding, while involvement of the small or large bowel may present as a change in bowel 
habits, bleeding and intestinal obstruction. (21) 
 
1.6.3. Systemic symptoms: 
Systemic symptoms may also occur. The onset of symptoms can be rapid and of short or long 
duration. A complex of systemic symptoms known as ‘B-symptoms’ are commonly present 
(fever, night sweats and unexplained weight loss) (see appendix A). 
The fever is usually low grade and may occur intermittently. It is believed to be due to the 
release of cytokines as the body tries to destroy the cancer cells. Drenching night sweats are 
also well described in lymphoma. However, sweating is not limited to the night only (but is 
perceived more readily at night). Usually the night sweats improve with treatment. However, 
the sweating may continue despite treatment, or occur even after treatment. Unexplained weight 
loss, which is unintentional, is described as ≥ 10% of loss of body weight, within the preceding 
six months. Due to the high energy demand by the rapidly multiplying cancer cells, cytokines 
which contributes to weight loss, are released. (17) 
It is important to note that ‘B-symptoms’ are not exclusive to lymphoma. Therefore, other 
possible causes of the ‘B-symptoms’ must be excluded. These include infections such as 
tuberculosis, brucellosis, highly active metabolic states such as hyperthyroidism, recurrent 
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episodes of hypoglycaemia, and the menopausal state in females, which may produce ‘hot 
flushes’. The presence of unexplained ‘B-symptoms’ usually implies disease activity and an 
adverse prognosis. They are, therefore, regarded as good markers of treatment response and 
relapse, if present. (11,17,18)  
 
1.7. Diagnosis of DLBCL: 
The best way to diagnose DLBCL is to obtain adequate tissue by excisional biopsy. A wedge 
or incisional biopsy may also be acceptable. This must be sent for relevant histological analysis. 
Fine Needle Aspiration (FNA) is inadequate for lymphoma diagnosis and generally not advised. 
Most of the FNA results are inconclusive as the amount of tissue obtained is very scanty and 
the cytopathologist is unable to comment on the architecture of the ‘lymph node’ and the pattern 
of involvement (as the tissue available is limited). (11) Following on a formal tissue biopsy, an 
experienced haematopathologist is required to analyze the histological specimen for the 
diagnosis of lymphoma. (22)  
The typical antigens expressed on the surface of the B-cells of DLBCL are: (cluster of 
differentiation) CD19, CD20, CD22, CD45 and CD79a. The GC subtype usually expresses 
CD10. The GC subtype usually expresses CD10. The Anaplastic variant of DLBCL may also 
express the CD30 antigen. The distinguishing factor from blastic mantle lymphoma will be their 
lack of cyclin D1 expression. (7,15,22)   
 
1.8. Staging of DLBCL: 
Staging of malignancies was formalized in the United States in 1959. Apart from anatomical 
sites, other factors taken into consideration include symptoms, laboratory results and tumour 
differentiation. (22,23) 
1.8.1. Biochemical staging: 
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Staging of DLBCL can be divided into the initial staging for planning of treatment, and the later 
restaging (post-treatment) to assess the response of the disease to treatment.  
Staging of DLBCL begins with clinical history and examination. It is then followed by basic 
laboratory parameters such as the Full blood count (FBC), Urea and electrolytes (U&E), Uric 
acid (UA), Liver function tests (LFT’s) and Lactate dehydrogenase (LDH). (14,15,22,23) The 
finding of an increased white cell count on the FBC, may imply an infection or possibly 
lymphoma. Lymphoma cells may occasionally spill over into the peripheral blood.  However, 
it is important to exclude leukaemia when there is spill of abnormal cells in the peripheral blood. 
Lactate dehydrogenase (LDH) is an enzyme that is secreted by most tissues. In the case of 
lymphoma, the secretion is from cells adjacent to the lymphomatous growth-stressed out cells. 
LDH is present as 5 different iso-enzymes and is increased in other conditions such as 
haemolysis. As a result, it cannot be used to diagnose the presence of lymphoma, but can be 
used as one of the markers indicating adverse prognosis, and in monitoring the response of 
lymphoma to treatment, or the relapse of lymphoma after treatment. Other tests include a serum 
calcium, serum protein electrophoresis (SPEP) to exclude a monoclonal gammopathy, viral 
studies (in particular Epstein-Barr virus (EBV), hepatitis virus and HIV; in some circumstances, 
(human herpes virus) HHV-8 and (human T-cell lymphotropic virus) HTLV-1), uric acid and 
beta-2 microglobulin. (11,14,15,22,23) 
 
1.8.2. Radiological staging (imaging): 
Chest X-ray is important as part of imaging. A positron emission tomography/computer 
tomography (PET/CT) scan or (computer tomography) CT scan of the head and neck, chest, 
abdomen and pelvis is required to define and document the extent of the disease 
involvement/spread. The initial scan is referred to as the staging scan. A restaging scan is used 
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in monitoring of the disease response to treatment. Follow up scans are also required to confirm 
ongoing remission and exclude relapse of disease. (23,24) 
1.8.3. Other modes of staging: 
A bone marrow aspirate and trephine (BMAT) is necessary to rule out involvement of the bone 
marrow by disease. Lumbar puncture is necessary, especially in patients at high risk for CNS 
disease (e.g. involvement of the nasal cavity/sinuses, oral cavity, extranodal disease, 
widespread disease). (7,22,23) 
1.8.4. Restaging: 
Restaging of DLBCL involves repeat of the relevant laboratory tests that were initially 
abnormal. If 6-8 cycles of treatment is planned, initial restaging is usually performed after 
completing 4 cycles of treatment. PET/CT is the recommended mode of imaging in restaging. 
(23,24,25) However, if it is not readily available a CT scan will suffice.  
1.8.5. Ann Arbor Staging: 
Staging is based on the Ann Arbor staging classification and the Cotswold modification of the 
Ann Arbor staging classification. (26,27) 
The Ann Arbor staging system is used for both Hodgkin lymphoma and NHL. It is divided into 
four stages (see Table 1.3 below). 
Table 1.3: Ann Arbor staging classification (26) 
Stages  Features 
 I Involvement of a single group of lymph nodes on one side of the 
diaphragm 
 II Involvement of two or more groups of lymph nodes on the same side of 
the diaphragm  
III Involvement of groups of lymph nodes on both sides of the diaphragm 
IV Diffuse or disseminated involvement of one or more extralymphatic 
organs, with or without lymphatic involvement 
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For all stages: 
 A – no ‘B-symptoms’ associated with the staging 
 B – ‘B-symptoms’ (fever > 38°C, drenching night sweats, weight loss of ≥10% body 
weight over 6 months) 
Extranodal sites of involvement include the liver, bone marrow/bone, spleen, thyroid, breasts, 
CNS, etc. However, ‘true’ extranodal disease involves sites other than the liver, spleen and bone 
marrow. 
To determine the staging of DLBCL, clinical examination and imaging, particularly the CT 
scan, are extremely important. The CT scan or PET/CT helps in determining the extent of both 
nodal and extranodal involvement. PET/CT is a new modality in delineating bone marrow 
involvement. (25-26) 
Immunochemistry is very helpful to the haematopathologist. It assists in accurately informing 
the type of lymphoma present. The cluster of differentiation markers (CD markers) on the 
surface of the cells will help to further specify the type of lymphoma present. This may be 
determined by flow cytometry or immunohistochemistry. (24,28,29) 
 
1.9. Performance status: 
Performance status (PS) must be assessed in all patients diagnosed with DLBCL. PS is a 
measure of the baseline functional capability of a patient, at the time of presentation. There are 
a few scoring systems used for assessing the performance status of patients with cancer, 
including lymphoma. The commonly used (PS) scales are: the Eastern Cooperative Oncology 
Group (ECOG) performance score, the Karnofsky performance score and the World Health 
Organization (WHO) performance score. These scoring systems assist in and contribute to the 
prognosis of the patient at presentation. A patient presenting with a more advanced score 
generally has a less favourable prognosis. Scoring systems also assist with/in assessing patients 
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for tolerability of treatment. Performance status scores are, additionally, helpful in clinical trials, 
where patients need to be categorized prior to entry into a study or prior to randomization. (30) 
The Eastern Cooperative Oncology Group (ECOG) PS score was published in 1982 for public 
use. It is now one of the most widely used performance scoring systems. Scoring according to 
ECOG is divided into 6 categories (see Table 1.4). (31) 
 
Table 1.4: ECOG performance status (31) 
SCORE EXPLANATION 
0 Asymptomatic 
1 Symptomatic but fully ambulatory 
2 Symptomatic but in bed < 50% of the day 
3 Symptomatic and in bed > 50% of the day, but not bedridden 
4 Bedridden 
5 Dead 
 
Karnofsky performance score/index also looks at the functional capabilities of a cancer patient. 
The scoring ranges from 100 down to 0. The lower the score, the poorer the functional status. 
The survival rate deteriorates as the score decreases. (30,32) 
The WHO performance score is similar to the ECOG performance score.  
 
1.10. Management of DLBCL: 
Diffuse large B-cell lymphoma (DLBCL) is a potentially curable, chemosensitive disease. The 
management broadly entails appropriate supportive care and specific modalities of treatment, 
with combination chemotherapy being the mainstay of specific treatment. 
Supportive care includes: 
a) Psychosocial and educational support 
b) Correction of fluid and electrolyte imbalance 
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c) Appropriate use of blood and blood products 
d) Analgesia and allopurinol 
e) Use of antibiotics to treat infections; use of growth factors in neutropenic patients, where 
indicated; use of antibiotic prophylaxis in selected patients (e.g. bactrim in HIV seropositive 
patients with CD4 counts <200 cells/ul) 
f)  CNS prophylaxis 
g) Concomitant use of combination antiretroviral therapy in all HIV seropositive patients, 
irrespective of the CD4 count. 
Specific modalities of treatment include: 
a) Chemotherapy – e.g. cyclophosphamide, doxorubicin, vincristine, prednisone 
(CHOP)/rituximab-CHOP/cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone 
(CHOEP)/R-CHOEP, other 
b) Monoclonal antibodies, including rituximab (usually in combination with chemotherapy such 
as R-CHOP) 
c) Radiotherapy (used in patients with CNS disease, including spinal cord compression and for 
bulky disease, where it is administered to the involved field – involved field radiotherapy 
(IFRT) 
d) Stem cell transplantation (usually autologous transplants, indicated for relapsed patients with 
chemosensitive disease) (7) 
e) Experimental/newer modalities of treatment. This includes the use of immunomodulatory 
drugs such as lenalidomide in combination with R-CHOP for non-GCB-cell like DLBCL, the 
use of bruton tyrosine kinase inhibitors such as ibrutinib, and exploration of new frontiers 
in immuno-oncology with the use of new monoclonal antibody-drug conjugates, checkpoint 
inhibitors and CAR (chimeric antigen receptor) -T cell therapy. (33,34) 
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In 1972, “based on phase 2 studies”, 35% of patients with NHL achieved a complete remission 
(CR) using the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). 
CHOP became the initial gold standard treatment for NHL, and still remains as the back-bone 
on which other treatments have developed. However, not all patients treated with CHOP will 
have the same response to treatment. This implies that there is heterogeneity of NHL and of 
DLBCL. The use of CHOP is applicable to both young and old individuals with NHL. However, 
up to 50% of patients relapse after initial CHOP therapy. (1,7,33) 
Initial trials that compared CHOP to second or third generation combination chemotherapy 
regimens (e.g. m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, 
vincristine, dexamethasone), ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, 
prednisone, intrathecal methotrexate), showed no survival difference over CHOP. (1,7)   
However, the addition of Rituximab (an anti-CD20 monoclonal antibody) to CHOP (R-CHOP) 
has significantly improved the outcome of patients with DLBCL. This was initially shown in 
the Grouped’Etude de Lymphomed’Adultes (GELA) study, which was undertaken to treat 
adults with DLBCL, who were 60 years of age and more. Trials such as the US Intergroup, the 
Rituximab with CHOP over age 60 years (RICOVER-60), the Mabthera international trial 
group (MINT) and the unselected population studies in British Columbia Province, supported 
the use and benefit of R-CHOP. (1,22,33-35) 
The CR, using CHOP only, was found to be 63%, while the use of R-CHOP improved the CR 
to 76%.(34) In addition, the event-free survival and overall survival was superior with R-CHOP 
compared to CHOP, without a clinically significant increase in toxicity. (34) This and several 
other studies formed the basis for rendering R-CHOP as the new standard of treatment for newly 
diagnosed patients with DLBCL.(34,35) 
Patients with DLBCL may present with extranodal disease at presentation or at relapse. Patients 
with DLBCL are at risk of central nervous system disease (primary CNS disease or systemic 
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lymphoma with secondary involvement of the CNS, most commonly as leptomeningeal 
disease). As such, intrathecal chemotherapy is beneficial in such patients with a high risk of 
CNS disease. CNS prophylaxis should be considered in the following categories of patients 
with DLBCL. (36-38) 
 Epidural disease  
 Testicular involvement 
 Breast disease  
 Bone marrow involvement 
 Bone disease 
 Nasopharyngeal disease 
 Extensive, widespread disease (stage IV) and 
 High lactate dehydrogenase (LDH) levels    
The prophylactic treatment for such patients is methotrexate ± cytarabine, and hydrocortisone, 
given intrathecally (total of 4 to 6 treatments for prophylaxis), ± high dose IVI methotrexate. 
The relapse rate of CNS disease in patients receiving prophylactic intrathecal chemotherapy 
was found to be 1 to 2%, compared to studies in which high risk patients for CNS disease were 
only given standard chemotherapy without prophylactic intrathecal chemotherapy, where the 
CNS relapse rate was found to be 2 to 8%. (36-38) CNS relapse occurs early in the diagnosis 
of highly aggressive subtypes of NHL, like Burkitt lymphoma (where the incidence is 
approximately 30%). Additionally, the use of R-CHOP has been to shown to lower the 
incidence of CNS relapse. (15,22)  
The CNS relapse can be predicted from several factors, some already discussed above. These 
factors also include the international prognostic index (IPI). The IPI assesses 5 year survival of 
patients with aggressive lymphomas, like DLBCL. It has 4 risk factor categories, as discussed 
in 1.11 below.   (15) 
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Risk factors for CNS relapse as indicated above are an IPI > 2, > 1 extranodal site of 
involvement (bone marrow, breast, kidney, adrenal gland, bone), elevated ECOG PS, raised 
LDH, stage intravenous (IV) disease, age > 60 years, failure to achieve complete remission and 
treatment without rituximab. (36-39) 
ICE (Ifosfamide, carboplatin, etoposide) or R-ICE (with the addition of rituximab), DHAP 
(dexamethasone, high-dose cytarabine, cisplatin) or R-DHAP, ESHAP (etoposide, solumedrol, 
high-dose cytarabine, cisplatin) or R-ESHAP may be used in relapsed patients. Chemosensitive 
patients with relapsed disease should be considered for an autologous stem cell transplantation 
(ASCT). (1,15,39,40) R-ICE has been shown to induce a non-significantly higher remission 
rate than R-DHAP. However, R-DHAP has a higher remission rate in the treatment of the GCB 
subtype of DLBCL. (15,39,40) 
  
1.11. Prognosis of DLBCL: 
The International Prognostic Index (IPI) was formulated to identify patients at high risk of 
relapse. The IPI was formulated at an International NHL Prognostic Factors project in 1993. 
(41) It is an important tool that is applicable to all patients with aggressive lymphomas, such as 
DLBCL. The IPI looks at the 5 year survival of patients, and has an overall survival range 
between 26% for high risk disease and 73% for low risk disease. Since the addition of rituximab 
to standard treatment protocols of DLBCL, the IPI has shown improvement in survival and 
prognosis of the affected patients. Four risk groups for relapse were identified by the use of the 
IPI: 
1. Low risk – 0,1 factors 
2. Low to intermediate risk – 2 factors 
3. High to intermediate risk – 3 factors 
         4.       High risk – 4,5 factors 
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The negative prognostic factors that determine these groups, as identified by the IPI, are shown 
in table 1.5: 
Table 1.5: Negative prognostic factors of the IPI (15,41) 
 Parameter Prognostic factors 
1. Age Age > 60 
2. Ann Arbor staging Ann Arbor stages 3 and 4 of the disease 
3. Blood Increased Lactate Dehydrogenase enzyme (LDH) 
4. Performance status ECOG performance status ≥ 2 
5. Extranodal involvement More than 1 extranodal site of the disease. 
 
More recent studies have shown the IPI to be more predictive in DLBCL than other categories 
of aggressive NHL. There is a strong correlation of survival with the IPI. This correlation was 
shown to be true for the use of R-CHOP in the unselected population study in the British 
Columbia Province. This study led to the revision of the IPI (R-IPI). (42) 
The study in the British Columbia province retrospectively looked at the impact of R-CHOP on 
the IPI over a 24 year period (1981 to 15 January 2005). Over 10 000 records of patients 16 
years old or more, were reviewed. Only newly diagnosed patients with DLBCL and who were 
CD20 positive, were looked at. All the patients were given R-CHOP with the intention to cure 
the disease. Patients with HIV, second malignancies, underlying indolent lymphoproliferative 
disorders and those with major coincidental illnesses precluding intention to cure, were 
excluded from the study. (42) Two outcomes that were looked at were: the Progression-free 
survival (PFS) and the Overall survival (OS), which implies the date of diagnosis of the disease 
to the date of documented progression of the disease (PFS) and, the date of diagnosis of the 
disease to the date of death due to any cause or the date of last known survival (OS), 
respectively. The end result was the formulation of a revised IPI (R-IPI). This led to the 
prognostic categories as shown in Table 1.6 below.  
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Table 1.6: Revised IPI score (42) 
Prognosis Number of negative risk factors present 
Very good No risk factors 
Good 1 to 2 risk factors 
Poor 3 to 5 risk factors 
 
The 4 year survival for the new groups, according to the R-IPI, was 53% to 94% for the PFS 
and 55% to 94 % for the OS. After establishment of the R-IPI, some negative factors lost their 
adverse prognostic status (e.g. molecular prognostic markers like BCL2 and BCL6). (42) 
Furthermore, an age-adjusted IPI (aaIPI) has been applied to clinical studies and predicts 
outcome in relapsed or primary refractory diffuse large B-cell lymphoma as well as acquired 
immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma. (43,44) Three factors 
are used in the aaIPI. These include LDH, stage and performance status, with further 
characterization as follows: low risk (0 factors); intermediate risk (1 factor) and high risk (2 or 
3 factors). (43) 
Apart from the IPI and its modifications, other negative prognostic factors in DLBCL include : 
(45) 
 A decrease in absolute lymphocyte count at the time of diagnosis 
 Loss of HLA-DR expression on the surface of the cells of DLBCL 
 The presence of MYC aberration  
 Non-GCB-type of DLBCL (Activated B-cell-like)  
 MYC/BCL2 co-expression 
 Genetic presence of: CCND2/SCYA3  
 Immunoblastic morphology of the lymphoma 
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1.12. HIV and DLBCL: 
High grade B-cell NHL is one of the three AIDS defining malignancies. The other two 
malignancies include Kaposi’s sarcoma and invasive carcinoma of the cervix. These three 
malignancies relate directly to the degree of immunodeficiency by HIV. DLBCL is the most 
common subtype of High grade B-cell NHL that occurs in HIV. It contributes 40-60% of the 
cases. Patients with HIV have a risk of developing NHL, 60-200 times more than the general 
population. (13,46-48) 
The introduction of anti-retroviral therapy in 1996 has resulted in a relative reduction in the 
incidence of NHL. (46) The introduction of cART in Western countries has resulted in an 
increased lifespan of individuals with HIV. The subsequent increased longevity has resulted in 
an increase in the incidence of malignancies including Hodgkin lymphoma due to longevity, 
rather than due to HIV infection alone. (49)  
The pathogenesis of HIV-associated NHL is multifactorial. It involves an interplay of multiple 
factors such as co-infection of oncogenic viruses (e.g. EBV), chronic antigen stimulation, 
genetic factors, and cytokine dysregulation. (48) Germinal center and post-germinal center 
subtypes of lymphoma may complicate HIV (see Figure 1.2 below). (48)  
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Figure 1.2: A model for the histogenesis of HIV-associated lymphomas showing molecular 
and viral pathogenesis and DLBCL taxonomy. BL indicates Burkitt lymphoma; DLBCL, 
diffuse large B-cell lymphoma; CB, centroblastic; IB, immunoblastic; PEL, primary effusion 
lymphoma; and PB, plasmablastic lymphoma. (48) 
 
In South Africa, the perceived incidence of HIV-associated lymphoma is on the increase 
(13,49). This is particularly true at CHBAH, Soweto, Johannesburg, where both NHL and HL 
are on the increase. (13,49) In general, patients with HIV-associated NHL tend to be younger 
(median age of 36 and 39 years respectively), have a slight male predominance (1.35:1 and 
1.1:1 respectively), present with more advanced stage disease, more frequent ‘B’ symptoms, 
more bulky disease, more frequent involvement of extranodal sites, more aggressive 
histological subtypes, and an inferior prognosis. (13,49,50) DLBCL is the most frequent 
histological subtype, accounting for 43.5% of the patients with HIV seropositivity (13), while 
Burkitt lymphoma, Plasmablastic lymphoma, High grade B-cell lymphoma, NOS (which 
includes the 2008 category of B-cell lymphoma, unclassifiable, with features intermediate 
between DLBCL and BL and High grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 
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translocations (previously referred to as ‘double-hit/triple-hit lymphomas’) are encountered 
with increased frequency in HIV-seropositive individuals. (4,5,13,47,51,52) 
In addition to the above, it is well recognised that lymphoma diagnosis in HIV-seropositive 
patients in the South African setting poses unique challenges. This includes the overlap and 
mimic of benign conditions such as tuberculosis (TB) masquerading as lymphoma. Moreover, 
TB may coexist with lymphoma. (13,49) Additionally, lymphomas in the local setting may 
present with atypical clinical features as well as atypical pathological features as indicated 
above (13,49) 
The management of DLBCL in the context of HIV-seropositivity is generally similar to the 
management in seronegative individuals, with a few areas of particular focus and concern. 
There is no doubt that concomitant combination antiretroviral therapy forms the cornerstone of 
management in these individuals, together with combination chemotherapy. Moreover, it is now 
being recognised that the survival outcome may be similar to seronegative individuals, if 
chemotherapy is combined with antiretroviral therapy. (48,53) Therefore, all patients should be 
commenced on combination antiretroviral therapy as soon as the diagnosis of lymphoma is 
made or continue combination antiretroviral therapy if they are already on treatment. 
Opportunistic infections such as TB and myelosuppression are more common in HIV 
seropositive patients. (13,49) A high index of suspicion, appropriate antibiotic prophylaxis and 
judicious use of growth factors help to overcome these challenges in such patients. 
The use of rituximab may be associated with a higher infection risk, particularly in individuals 
with very low CD4 counts. (53) However, the addition of rituximab to chemotherapy, whether 
it be standard chemotherapy such as CHOP or infusional regimens such as CDE 
(cyclophosphamide, doxorubicin, etoposide) or EPOCH, increases the CR rate and the overall 
survival (OS) rate. (53,54) A recent pooled analysis of 1546 patients with HIV-lymphoma 
treated with rituximab showed improved CR and OS, with a slight increase in opportunistic 
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infections, no increase in second malignancies and no unexpected long term toxic side effects. 
(54) Similar regimes to HIV-seronegative patients may be used in relapse and autologous stem 
cell transplantation is feasible in patients with chemosensitive disease. (55) 
Overall, in the last two to three decades, the clinical demographic of HIV-associated 
lymphomas have evolved, and the outcomes have improved due to the introduction of combined 
antiretroviral therapy, improvements in the management of opportunistic infections and the 
application of more appropriate and improved combination chemotherapy.  
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CHAPTER 2 
2. PATIENTS AND METHODS 
2.1. Aim: 
To review the profile of adult patients with DLBCL at Chris Hani Baragwanath Academic 
Hospital (CHBAH) over a 5 year period: 1st January 2008 to 31st December 2012. 
 
2.2. Study Objectives: 
i. To describe the demographics, clinical presentation, diagnostic tools, staging, 
prognostic factors and management of patients with a histological diagnosis of 
DLBCL. 
ii. To describe the impact of HIV in these patients. 
 
2.3. Study design: 
A retrospective review of adult patients admitted to the Clinical Haematology Unit, Department 
of Medicine, CHBAH, from 1st January 2008 to 31st December 2012.  
 
2.4. Sample population: 
In total, 451 patients were diagnosed with NHL between 2008 and 2012. Of these patients 156 
(35%) were diagnosed with DLBCL. However, for various reasons such as inadequate 
information, incomplete work-up, death prior to initiation of chemotherapy, only 139 patients 
(89%) were evaluated for the current study. 
 
2.5. Inclusion criteria: 
 Histologically confirmed diagnosis of DLBCL. 
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2.6. Exclusion criteria: 
Patients with lymphoma, other than DLBCL (e.g. Burkitt lymphoma, Follicular lymphoma, T-
cell lymphomas) were excluded from the study. 
 
2.7. Collection of data: 
This entailed a retrospective review of records/files of inpatients and outpatients with DLBCL 
during the period 1st January 2008 to 31st December 2012. Permission to look at the files was 
obtained from the Chief Executive Officer (CEO) of the Hospital, the Head of Internal Medicine 
and the Head of the Clinical Haematology Unit, Department of Medicine. Data was collected 
using a questionnaire (see Appendix A and Appendix B).  
Data collection focused largely on the objectives of the study (demographics, clinical 
presentation, diagnostic tools, prognostic factors and management). It was then transferred to 
an excel spreadsheet for statistical analysis. 
 
2.8. Data analysis: 
For variable data such as age, gender, geographic location and race, descriptive analysis was 
used. For continuous variables, statistical analysis such as mean, median and standard deviation 
were used. Percentages and proportions were used for categorical data. For comparison of data, 
the chi-square test of association was used (to assess the relationship between two categorical 
variables). 
The Instat program was used for further data analysis. Assistance from a statistician was sought 
and all data was stored in a Microsoft excel program. 
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2.9. Study significance: 
It is hoped that the current study will add to the limited existing information on the 
epidemiology, clinical features, diagnosis and management of patients with DLBCL in the 
South African context. The study will also provide an idea of the impact of HIV on an increasing 
incidence of DLBCL in South Africa. Furthermore, the findings of the study will allow a 
comparison with that of other studies done locally and internationally.  
 
2.10. Ethical consideration: 
The study was commenced after confirmation of approval by the Human Research Ethics 
Committee (HREC) of the University of the Witwatersrand. To ensure confidentiality of the 
patients, study numbers were used instead of the patient names. Furthermore, the age of the  
patient  as opposed to the date of birth was used. 
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CHAPTER 3 
3. RESULTS 
3.1. Demographics: 
A total of 139 patients with DLBCL were reviewed. The vast majority were from the Gauteng 
province - 83%, with 6% from the Northwest, 2% from Mpumalanga and 1% from KwaZulu 
Natal. In 8% of patients, the location was unknown. Foreign patients from outside South 
Africa were included in the Gauteng province as they provided addresses from this province 
(see Figure 3.1).  
 
Figure 3.1: Demographic distribution of the patients 
 
It is also possible that patients coming from other provinces may have used addresses in 
Gauteng in order to gain admission to CHBAH. 
There were 73 females and 66 males in the study, with a female to male ratio of 1.1:1 (see 
Figure 3.2 and Table 3.1).  
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Figure 3.2: Gender distribution of the patients 
 
Table 3.1 : Gender distribution of the patients 
Variable Category Number  Percent  
Gender 
Male 66 47.5 
Female 73 52.5 
Gender Ratio 1.1:1  
 
The majority of the patients were Blacks (95%), with patients of mixed race (coloureds) making 
up 2%, and Indians and Whites 1% each, respectively (see Figure 3.3).  
 
 
Figure 3.3: Ethnic distribution of the patients 
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The mean age of the patients was 42.75 years with a standard deviation of 12.126 years.  The 
median age was 41 years, with a range of 14-85 years (see Figure 3.4). 
 
Figure 3.4: Age distribution of the patients 
 
3.2. Clinical presentation: 
The symptoms and signs at presentation are indicated in Table 3.2 below.  
Table 3.2: Symptoms and signs at presentation 
 Frequency Percent 
Unexplained weight loss 94 68% 
Night sweats 76 55% 
Fever 58 42% 
B Symptoms(at least one present) 103 74% 
Infections 29 21% 
Pallor 23 17% 
Jaundice 27 19% 
Bleeding and other  - - 
Lymphadenopathy 89 64% 
Splenomegaly (Clinical) 2 1% 
Hepatomegaly (Clinical) 25 18% 
Organ involvement   
GIT 22 16% 
CNS 5 4% 
Respiratory 19 14% 
Renal  2 1% 
Bone marrow 12 9% 
Other   
Multiple sites 29 21% 
Skin 1 1% 
Gynaecological 2 1% 
Breast 2 1% 
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Records on 139 patients were evaluated for this study. Constitutional symptoms or ‘B’ 
symptoms were common. The breakdown of ‘B’ symptoms was as follows:  
 Unintentional weight loss – 68% (n=94) 
 Night sweats – 55% (n=76) 
 Fever – 42% (n=58) 
The most common ‘B’ symptom was weight loss. At least one ‘B’ symptom was present in 105 
(76%) of the patients.  
Regarding performance status (PS), 53% (n=73) had either a PS of 0 or 1. Fourteen patients 
(10.1%) had a PS of 2, while 10 patients (7.2%) and 14 patients (10.1%) had a PS of 3 or 4, 
respectively. Therefore, 27.4% (n=38) had a PS ≥2. PS was unknown (not clearly documented) 
in 28 patients (20.1%) (see Table 3.3 below). If the patients in whom the PS is unknown is 
removed, then the percentages will be as follows: PS = 0 (29%); PS = 1 (37%); PS = 2 (12.5%), 
PS = 3 (9%) and PS = 4 (12.5%) 
Table 3.3: Performance status for all patients 
Performance   
 Frequency Percent 
0 32 23.0 
1 41 29.5 
2 14 10.1 
3 10 7.2 
4 14 10.1 
Unknown 28 20.1 
Total 139 100.0 
 
Lymphadenopathy was present in 89 patients (64%) at presentation, while hepatomegaly and 
splenomegaly was detectable clinically in 18% and 1% of patients respectively.  
Sites of diagnostic biopsies were clearly identifiable in 112 (81%) of the 139 patients. These 
sites are indicated in Table 3.4 below. 
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Table 3.4: Diagnostic biopsy sites 
Site of Diagnostic Biopsy Frequency Percent 
Gastrointestinal system (mouth → rectum) 22 15.8% 
Cervical lymph nodes 21 15.1% 
Axillary lymph nodes 11 7.9% 
Multiple sites (nodal/extranodal) 9 6.5% 
Inguinal lymph nodes 6 4.3% 
Chest wall lymph nodes 5 3.6% 
BMAT 5 3.6% 
Pre-auricular lymph nodes 5 3.6% 
Spinal mass 4 2.9% 
Skin lesions 4 2.9% 
Supraclavicular lymph nodes 3 2.2% 
Tonsillar mass 3 2.2% 
Liver biopsy 3 2.2% 
Gynaecological (endometrium and ovaries) 3 2.2% 
Femoral lymph nodes 3 2.2% 
Mesenteric lymph nodes 2 1.4% 
Respiratory system (lung) 1 0.7% 
Breast mass 1 0.7% 
Bone (knee) 1 0.7% 
 
The frequency of diagnostic biopsy sites in groups is shown in Figure 3.5.   
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Figure 3.5: Diagnostic biopsy sites in groups.  
(Other implies multiple sites, including both nodal and extranodal sites) 
 
Out of a total of 101 (73%) patients with extranodal disease, the disease was detected via 
imaging in 87% of the patients, while 83% of the patients had clinical evidence of extranodal 
disease. In 77% of the patients, extranodal sites were accessible for biopsy.  Therefore, a 
combination of diagnostic modalities provides a higher diagnostic yield, with respect to 
extranodal disease (see Figure 3.6). 
 
 
Figure 3.6: Diagnostic modalities to detect extranodal disease 
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3.3. Laboratory results and other diagnostic investigations: 
The laboratory results are shown in Table 3.5 below. 
Table 3.5: Laboratory results at presentation.  
Variable n Median Mean Range n (%) 
Haemoglobin (g/dl) 133 10.70 11.37 4.3 - 137  
Anemia < 11 133    73 (55%) 
White Cell Count (x109/l) 96 3.65 4.41 0.1 - 19.54  
Leukopenia < 4 96    57 (59%) 
Normal 96    34 (35%) 
Leukocytosis > 11 96    5 (5%) 
Platelets (x109/l) 132 335 355.73 7 - 899  
Thrombocytopenia < 100 132    6 (5%) 
Thrombocytosis > 450 132    34 (26%) 
LDH (U/L) 84 826.5 1254.12 174.3 - 8486  
Raised-ULN 84    82 (98%) 
Beta2 microglobulin (mg/l) 48 4.05 5.06 1.9 - 16  
Raised-ULN 48    42 (88%) 
Calcium (mmol/l) 92 2.345 2.38 1.89 - 4.48  
Hypercalcaemia > 2.75 92    2 (2%) 
Urea (mmol/l) 118 4.8 6.08 1.9 - 25.5  
Creatinineumol/l 119 66 80.18 27 - 715  
>173 119    4 (3%) 
Albumin (g/l) 99 32 31.74 14 - 53  
<40 99    83 (84%) 
<35 99    63 (64%) 
<30 99    37 (37%) 
Alkaline phosphatase (U/L) 97 97 149.72 40 - 1047  
Raised-ULN 97    45 (46%) 
GGT (U/L) 97 46 109.75 13 - 990  
Raised-ULN 97    36 (37%) 
CD4 Count (cells/ul) 101 144 205.37 3 - 1351  
<350 101    21 (21%) 
<200 101    31 (31%) 
<100 101    31 (31%) 
ULN = Upper Limit of Normal 
In addition to the above, the surface antigens on the biopsies (n=112) were analysed to 
determine or prove NHL. The most prominent antigen markers were CD79a (97%), CD20 
(68%), BCL6 (35%), CD10 (34%) and CD45 (29%). The proliferation index (Ki67) was > 80% 
in 41% of the patients (see Figures 3.7 and 3.8). 
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Figure 3.7: CD antigen markers 
 
 
 
Figure 3.8: Proliferative index (Ki67) 
 
 
3.4. Staging: 
The Ann Arbor stage for all the patients was determined clinically and on imaging studies. 
The stage is indicated in Table 3.6 below. 
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Table 3.6: Ann Arbor staging for all patients 
 
 
 
 
The IPI score was determined using the 5 parameters indicated in the introduction (see page 
18). The findings are shown in Table 3.7 below. 
 
Table 3.7: IPI score for all patients 
 Frequency Percent Cumulative Percent 
Valid Low risk 45 32.4 32.4 
Intermediate 
Low 
55 39.6 71.9 
Intermediate 
high 
33 23.7 95.7 
High risk 6 4.3 100.0 
Total 139 100.0  
 
3.5. HIV and DLBCL 
Of the total of 139 patients, 112 were found to be HIV seropositive (81%). Twenty one (21) 
patients (15%) were HIV seronegative and in 6 patients (4%) the HIV serology status was 
unknown. This is reflected in Table 3.8 below.  
 
Table 3.8: HIV status of the patients 
  Frequency Percent 
HIV Status 
Positive 112 81% 
Negative 21 15% 
Unknown 6 4% 
 
 
 Frequency Percent 
I 11 7.9 
II 9 6.5 
III 23 16.5 
IV 93 66.9 
Unknown 3 2.2 
Total 139 100.0 
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Of the 139 patients in the sample of patients diagnosed with NHL, 81% (n=112) were HIV 
seropositive, 15% (n=21) were HIV seronegative, while 4% (n=6) did not have records. Of the 
112 patients diagnosed with HIV seropositivity, only 82 patients had exact records to enable 
the calculation of descriptive statistics. The average of HIV seropositivity before diagnosis of 
NHL was 22.02 months. The median duration was 4.5 months. At presentation and diagnosis 
of NHL, 31.3% (n=35) of HIV seropositive patients (both known and newly diagnosed) were 
not on combination antiretroviral treatment (cART) (see Table 3.9 and Figure 3.12).  
Table 3.9: Status and duration of HIV  
  Frequency Percent 
HIV Status 
Positive 112 81% 
Negative 21 15% 
No records 6 4% 
Descriptive Statistics 
 N Minimum Maximu
m 
Mean Media
n 
Std. 
Deviatio
n 
Duration 
(months) 
82 0 156 22.02 4.50 35.529 
 
 
 
Figure 3.9: Duration of HIV 
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The mean age for HIV seropositive patients was 40.40 ± 8.89 years, with a median of 39.00 
years and a range of 14-66 years, while that of HIV seronegative patients was 52.76 ± 18.35, 
with a median of 53.00 years and a range of 22 to 85 years, respectively (see Table 3.10). 
 
Table 3.10: Analysis of HIV status by age and gender 
 HIV Status 
P-value 
Variable Category Positive (n=112) Negative (n=21) 
Age 
Mean 
Median 
40.40 ± 8.89 
39 
52.76 ± 18.35 
53 
0.003 
Gender 
Male 55 (48 %) 8 (38.5%) 
0.288 
 
Female 57 (52%) 13 (61.5%) 
Gender Ratio 
(female: 
male) 
1.04:1 1.6:1 
 
Analysis of the CD4 counts showed the median and mean to be 144 cells/ul and 205 cells/ul, 
respectively, with a range of 3-1351 cells/ul. The CD4 counts in 101 patients in whom the result 
was documented is shown in Table 3.11 below. 
 
Table 3.11: CD4 counts 
 Category Frequency Percent 
CD4 count 
(cells/ul) 
< 100 31 31% 
100  - 200 31 31% 
200 – 350 21 21% 
350 – 500 10 10% 
> 500 8 7% 
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3.5.1. Comparison of HIV seropositive and seronegative patients 
A comparison of the clinical presentation, laboratory features and outcome of HIV 
seropositive and HIV seronegative patients is shown in Table 3.12 below.  
 
Table 3.12 : Comparison of HIV seropositive and seronegative patients 
    All patients Positive Negative P-value 
Test 
Conducted 
   139 112 21     
Age at 
diagnosis   41 (14 - 85) 39 (14 - 66) 52 (22 - 85) 0.009 
Mann-
Whitney U 
Male: Female 
ratio   1 : 1.1 1 : 1.04 1 : 1.6 0.476 Chi-square 
% seropositivity     81% 15% 0.000 Chi-square 
B Symptoms   105 (76%) 84 (75.0%) 19 (90.5%) 0.159 Chi-square 
Ann Arbor 
Stage III/IV   
116 
(83.5%) 93 (83.8%) 19 (90.5%) 0.740 Chi-square 
LDH Increase   76 (54.7%) 64 (57.1%) 12 (57.1%) 1.000 Chi-square 
PFS ≥ 2   38 (27.4%) 30 (26.8%) 6 (28.6%) 1.000 Chi-square 
Extranodal 
disease   
101 
(72.7%) 80 (71.4%) 17 (81.0%) 0.434 Chi-square 
Positive TB 
Association   42 (30.2%) 38 (33.9%) 3 (14.3%) 0.120 Chi-square 
IPI score 
Low risk 45 (32.4%) 38 (33.9%) 3 (14.3%) 
0.038 Chi-square 
Intermediate 
Low 55 (39.6%) 44 (39.3%) 11 (52.4%) 
Intermediate 
high 33 (23.7%) 27 (24.1%) 4 (19.0%) 
High risk 6 (4.3%) 3 (2.7%) 3 (14.3%) 
ABC/GCB 
GCB 48 (34.5%) 36 (32.1%) 10 (8.9%) 
0.191 Chi-square 
ABC 36 (25.9%) 31 (27.7%) 3 (2.7%) 
Mixed 23 (16.5%) 19 (17.0%) 2 (1.8%) 
No records/ 
Failed 32 (23.0%) 7 (6.3%) 0 (0.0%) 
Outcome 
Alive 30 (21.6%) 25 (22.3%) 4 (19.0%) 
0.845 Chi-square 
Dead 56 (40.3%) 44 (39.6%) 10 (47.6%) 
Lost to 
follow up 49 (35.3%) 41 (36.6%) 7 (33.3%) 
Unknown 4 (2.9%) 2 (1.8%) 0 (0.0%) 
  
39 
3.6. Co-morbidities 
Co-morbid disease was evident in 30% of the patients. Co-morbidities included: tuberculosis, 
asthma, hypertension, diabetes, gout, multifibroid uterus, peptic ulcer disease, complicated TB 
meningitis (TBM), deep venous thrombosis, other (see Table 3.13). 
 
Table 3.13: Evidence of co-morbid disease 
  Frequency Percent 
Co-morbid Disease 
Yes 41 30% 
No 92 66% 
Unknown  6 4% 
 
Tuberculosis was the most significant co-morbidity in this study. Forty two patients (30%) had 
evidence of past or active (current) TB, accounting for 43% each with TB, respectively (see 
Table 3.14). Of the 43% with current TB, 10% had extrapulmonary TB. 
 
Table 3.14: Co-morbid Tuberculosis infection 
  Frequency Percent 
Details of TB 
Current 18 43% 
Past 18 43% 
Unknown 6 14% 
 
3.7. Management of DBLCL: 
3.7.1. Chemotherapy: 
All patients received supportive care. With regard to specific treatment, the majority of patients 
(124/139) received combination chemotherapy (89%). The remaining patients (11%), did not 
receive chemotherapy as they died shortly after the diagnosis, or during their work up for NHL. 
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Of 124 patients that received chemotherapy, CHOP (95%) was the most commonly used initial 
therapeutic regimen (see Figure 3.13).  
 
 
Figure 3.10: Initial chemotherapy 
 
The patients were planned to receive 6-8 cycles of chemotherapy. A minimum of 1 cycle, to a 
maximum of 16 cycles of chemotherapy (mean of 5.36 cycles) was administered.  
Figure 3.14 shows the different second line chemotherapeutic regimes received, with CHOEP, 
R-CHOEP and R-CHOP being the most commonly used regimens. Multiple treatment regimens 
were used in 25% of the patients. 
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Figure 3.11: Second line chemotherapy. MTX (methotrexate) 
 
3.7.2. Prophylactic Treatment: 
Antibiotic prophylaxis and CNS prophylaxis was administered to a subset of patients with NHL, 
as indicated below (see also Tables 3.15 and 3.16).  
a. Pneumocystis Jiroveccii Pneumonia (PCP) – 19% 
b. Anti-TB prophylaxis – 6% 
c. Intrathecal (IT) chemotherapy prophylaxis – 19%. Four to 6 cycles were planned 
on the patients. An average of 5 cycles of IT was administered (see Table 3.16)  
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Table 3.15: Prophylactic treatment 
  Frequency Percent 
Prophylactic 
Treatment 
Yes 41 29% 
No 87 63% 
Unknown 11 8% 
TB 
Yes 9 6% 
No 113 81% 
Unknown 17 12% 
PCP 
Yes 8 6% 
No 111 80% 
Unknown 20 14% 
Intrathecal 
Chemotherapy 
Yes 27 19% 
No 95 68% 
Unknown 17 12% 
 
Table 3.16: Intrathecal chemotherapy 
Descriptive Statistics 
 n Minimum Maximum Mean Std. Deviation 
Number of 
intrathecal 
chemotherapy 
treatments 
27 1 9 5.00 2.236 
 
3.7.3. Other treatments used: 
Involved field radiotherapy was used as initial treatment in 5% of the patients for emergencies 
such as spinal cord compression and as adjunctive therapy in 9% of the patients for 
chemoresistant disease, ‘bulky’ diseaseor CNS involvement. 
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3.8. Response to treatment and survival: 
Thirty six patients (26%) achieved a complete response (CR), while 17 patients (12%) achieved 
a partial response (PR) to treatment. A total of 38 patients (27%) died during the treatment 
course and 48 patients (35%) had less than partial response, were lost to follow up, or the status 
of the patient was unknown (see Table 3.17).   
 
Table 3.17: Response to treatment 
  Frequency Percent 
Response to initial treatment 
(complete/ partial/ no response) 
Complete 36 26% 
Partial 17 12% 
Died 38 27% 
Lost to follow up/ 
less than partial 
response / 
unknown  
48 35% 
 
The median overall survival for the HIV seropositive patients was 21 months and for the HIV 
seronegative patients 24 months respectively (see Figure 3.15). The median survival was 24 
months for all the patients (see Figure 3.16).  
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Figure 3.12: Median overall survival 
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Figure 3.13: Median overall survival in the HIV seropositive and seronegative patients 
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CHAPTER 4 
4. DISCUSSION 
Non-Hodgkin Lymphoma (NHL) constitutes a heterogeneous group of haematological 
malignancies with a variable biological and clinical spectrum. (1) DLBCL is the most common 
subtype of Non-Hodgkin Lymphoma (NHL), accounting for 30 to 40% of NHL worldwide, and 
60-70% of the aggressive lymphomas of B-cell origin. (2,7,9) 
This study is a retrospective overview of DLBCL in adult patients at CHBAH, seen between 
the 1st January 2008 and 31st December 2012.  During this 5 year period, NHL was the most 
common haematological malignancy encountered in adult patients at CHBAH. DLBCL was 
indeed the most common subtype, accounting for 35% of the patients with NHL. However, this 
figure is lower than that noted in two previous studies conducted at CHBAH, where DLBCL 
accounted for 39.2% and 42.3% respectively. (13,54,55) This decrease could be explained by 
the increase in HIV seropositivity in this study and the association with a higher percentage of 
other histological subtypes that occur more frequently in the context of HIV seropositive 
patients, such as Burkitt lymphoma, plasmablastic lymphoma and the entity of B cell 
lymphoma, unclassifiable, with features intermediate between DLCBL and BL (as it was 
designated in the 2008 WHO classification). (4,13,50,52) 
The majority of patients with DLBCL were from the province of Gauteng (83%), where the 
healthcare facility is based. Understandably, 95% of treated patients were black (historical 
location, majority being from Soweto, Johannesburg). Studies conducted in the early 1990’s in 
South Africa at CHBAH showed only a modest increase in HIV associated NHL. By the early 
2000’s there was a steady increase in HIV associated NHL, this increasing trend has continued 
and can be directly correlated with an increase in HIV infection. (13) 
Of the 139 patients studied, there were 73 females (53%) and 66 males (47%), with a female to 
male ratio (1.1:1). This supports the trend that has been noted with particular reference to HIV, 
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where there is a higher female to male ratio. This is reflected in our HIV seropositive patients 
in this study, where there is a female to male ratio of 1.04:1. The younger median age of all the 
patients (i.e. 41 years) is in keeping with previous studies done at our institution and is a 
reflection of both the younger age structure of the population in Africa as well as the younger 
age at which HIV seropositive patients present. (13,54,55) 
Common presenting features in patients with DLBCL include peripheral lymphadenopathy 
(64%), which is the clinical hallmark of the lymphoproliferative disorders. Constitutional 
symptoms/’B’ symptoms were also commonly encountered (76%), with significant weight loss 
being the most common constitutional symptom in DLBCL. 
Extranodal disease is present in up to 40% of patients with DLBCL and involvement of 
extranodal sites is associated with an adverse prognosis. (1,9,13) A higher proportion of patients 
in our study exhibited extranodal disease (73%). This could be attributed to patients presenting 
late, with more advanced disease including involvement of extranodal sites, together with the 
significant burden of HIV seropositivity, where extranodal disease is more common. (13,54,55) 
It is also clear from this study that a combination of clinical assessment and appropriate imaging 
provides a higher diagnostic yield with respect to extranodal disease. There is no doubt that 
adequate biopsy material is required to properly characterise the subtype of NHL, with 
particular reference to morphology and immunohistochemistry.  
Approximately one third of patients with DLBCL have a performance status of ≥2 (27.4% and 
34% if the unknown component is removed), whereas approximately two thirds of the patients 
have a favourable performance status. This is an interesting observation and may be reflection 
of the greater tolerance of symptoms/disease manifestations in our patient population. 
The Cotswold modification of the Ann Arbor staging was used to assess stage in our patients. 
Not unexpectedly, 83% of the patients had advanced stage disease (stage III or IV).  
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With regard to the International Prognostic Index (IPI) score, approximately two thirds of the 
patients had an intermediate score (63%). A high risk score was uncommon, only accounting 
for 4.3% of patients. This is most likely attributable to the vast majority of patients being under 
60 years of age (94%) and the relatively good performance status at presentation in our patients.  
A review of the laboratory investigations shows that the mean haemoglobin was 11.3 g/dl,  
mean WCC was 4.41 x 109/l and  mean platelet count was 355 x 109/l, respectively.  Anaemia 
(Hb < 11 g/dl) was present in 55% of the patients, leucopenia (white cell count <4 x 109/l) in 
59%, leucocytosis (white cell count > 11 x 109/l) in 5%, thrombocytopenia (platelet count < 
100 x 109/l) in 5% and thrombocytosis (platelet count > 450 x 109/l) in 26% of the patients at 
presentation. Established renal impairment (after correction of dehydration and other 
modifiable factors such as electrolyte imbalance) was unusual (3%) and hypercalcaemia was 
rarely encountered (2%). The lactate dehydrogenase (LDH) was raised in 98% of the patients, 
while the Beta 2 microglobulin was elevated in 88% of the patients at presentation. An albumin 
of < 40g/dl was noted in 84% of the patients, while an albumin of < 30 g/dl was found in 37% 
of the patients. A raised alkaline phosphatase (ALP) and gamma-GT (GGT) were found in 46% 
and 37% of the patients, respectively.  
Of the 139 patients, 112 were found to be HIV seropositive (81%). This figure is higher than 
two previous studies done at CHBAH and confirms the ongoing and increasingly significant 
burden and contribution of HIV to NHL. (13) HIV seronegative patients accounted for only 
15% of the total number of patients, while in 4% the HIV status was unknown. At the outset, 
one of the study objectives was to assess the impact of HIV on DLBCL and to compare HIV 
seropositive and seronegative patients. While the impact of HIV is clear, given the small 
numbers of patients with HIV seronegativity, a comparison with HIV seropositive individuals 
in this study is less meaningful, from a statistical point of view.  Nevertheless, a few pertinent 
comments will be made with regard to the HIV.  
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A simultaneous diagnosis of HIV NHL (DLBCL) was seen in 25% of the patients. This is less 
than two previous earlier studies and suggests that individuals are being screened and tested for 
HIV more readily than previously. (54,55) The median age of HIV seropositive patients (39 
years) is statistically significantly (p=0.03) younger than HIV seronegative patients (52 years) 
and there is a slight female predominance of 1.04:1. The median CD4 count of the seropositive 
cohort is 144 cells/ul, with 62% of patients having a CD4 count < 200 cells/ul and 31% having 
a CD4 count < 100 cells/ul, at the time of the diagnosis of the DLBCL. This is consistent with 
HIV seropositive DLBCL lymphoma patients having a significantly lower CD4 count at 
presentation. (53) 
Table 3.12 shows a comparison of HIV seropositive and HIV seronegative patients. Statistically 
significant differences are only evident with respect to the following parameters: age at 
diagnosis (p value = 0.009; younger age associated with HIV seropositivity) and IPI score (p 
value = 0.038; less patients with low risk IPI and more patients with high risk IPI in seronegative 
group). As indicated previously, in view of the small number of patients with seronegativity, 
other differences were not statistically significant. However, the association with co-morbidities 
such as TB was higher in the HIV seropositive group (33.9%) versus the HIV seronegative 
group (14.3%). Hence, this remains an important challenge in our HIV- lymphoma population. 
(13,50,51) 
What is also noteworthy in Table 3.12, is the indirect evidence of all patients with DLBCL 
presenting late with advanced disease – ‘B’ symptoms present in 76%; advanced stage in 
83.5%; raised LDH in 98% and extranodal disease in 72.7%. These high percentages are seen 
in both the HIV seropositive and HIV seronegative patients. 
Interestingly, the GCB type of DLBCL (45%) was more common than the ABC type of DLBCL 
(34%) in patients in whom a positive test result was obtained. However, this difference was not 
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statistically significant, and moreover, there was no difference with regard to these subtypes in 
HIV seropositive and seronegative patients.  
Patients with DLBCL at CHBAH are treated in a similar way to other patients with DLBCL 
with respect to supportive care and chemotherapy as the mainstay of specific treatment. 
However, CHOP rather than R-CHOP was the standard of care in this cohort of patients. This 
practice has changed somewhat (subsequent to 2012, which is the end date of the study), with 
rituximab now being available to state hospitals and the increasing use of rituximab in HIV 
seropositive patients based on evidence of safety and efficacy in a number of studies and the 
initiation of a prospective, randomised study of R-CHOEP versus CHOEP in patients with 
DLBCL at CHBAH since 2014. (13,57,58) 
Based on the results of the patients treated in the current study, 38% achieved a response (26% 
- CR and 12% - PR). Thirty patients died (27%) and the remaining 35% includes patients who 
achieved less than a partial response and those who were lost to follow up. Among the patients 
who died and who were lost to follow up, the response to treatment has not been documented. 
It is possible that variable responses could have been encountered, ranging from complete 
response and death due to another cause, to progression of disease. 
The median overall survival for all the patients in the study was 24 months. This generally 
poorer survival is attributed to significant delays in diagnosis and subsequent late referrals, late 
presentations with more advanced stage disease, more ‘B’ symptoms, more extranodal disease 
as well as the significant impact of HIV on NHL, presenting with this more aggressive 
histological subtype, atypical clinical and laboratory features, and the attendant comorbidities 
such as tuberculosis and other opportunistic infections, more myelosuppression, delays in 
giving chemotherapy on schedule, and ultimately, a poorer prognosis. 
NHL is the most common haematological malignancy encountered in adults at CHBAH. 
DLBCL accounts for 35% of all the patients with NHL. HIV seropositivity is present in 81% 
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of the patients with DLBCL and has a significant impact with regard to the presentation and 
outcome of the patients in our study. More recently, with the early introduction and continuation 
of cART, the institution of appropriate antibiotic and CNS prophylaxis, the more liberal use of 
growth factors and more optimal chemotherapy with the early introduction of etoposide and 
rituximab and the use of autologous stem cell transplantation in patients with relapsed, 
chemosensitive disease, it is hoped that the outcome of patients with DLBCL treated at 
CHBAH, will improve significantly compared the outcome of the patients in this retrospective 
study. 
Limitations with regard to this study include: 
 Patients in whom the histology is unclear or incomplete 
 Patients dying before adequate tissue could be obtained 
 Patients diagnosed somewhere else and where the diagnosis is difficult to verify 
 Patients who are lost to follow up (incomplete data with regard to follow up, 
survival and outcome) 
 Incomplete and inadequate records 
 Missing records 
This resulted in variability in some of the analysis. These problems are likely to persist in a 
large hospital such as CHBAH. A prospective, randomised study, with meticulous 
documentation of results and follow up of patients should ideally be performed. Currently, a 
study of this nature in HIV seropositive patients is being undertaken at CHBAH. This study 
also aims to clarify the exact role of rituximab (which has become the standard of care in most 
subsets of NHL, including DLBCL) in HIV seropositive patients.  
For patients who do not fulfil the inclusion and exclusion criteria and who have DLBCL, every 
attempt should be made to document all the patient information, including follow up and 
response to treatment, so that the gaps in our current, retrospective study can be minimised. 
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CHAPTER 5 
5. CONCLUSION 
Diffuse large B-cell lymphoma (DLBCL) is the commonest subtype of NHL, accounting for 
30-40% of NHL worldwide. In South Africa, DLBCL remains the commonest subtype of NHL, 
with 35% of all NHL patients during this study period, harbouring DLBCL. 
Of the 139 patients studied, there were 73 females (53%) and 66 males (47%), with a female to 
male ratio of 1.1:1. The median age at presentation was 41 years. 
Adverse prognostic factors were common, with ‘B’ symptoms being present in 76%, extranodal 
disease in 73%, an elevated LDH in 98% and advanced stage disease in 83% of patients, 
respectively.  
Human immunodeficiency virus (HIV) infection had a major impact on the study population, 
with 81% of the patients being seropositive. HIV seropositive patients presented at a younger 
age of 39 years and had a female to male ratio of 1.04:1. A direct comparison between HIV 
seropositive and HIV seronegative individuals was less meaningful in this study, in view of the 
small number of HIV seronegative patients. However, adverse prognostic factors were 
consistently noted in the HIV seropositive patients, similar to the entire cohort (i.e. all the 
patients). In addition, tuberculosis was a comorbidity in this subset of patients. 
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APPENDIX A (DLBCL-Data collection sheet) 
 
DLBCL-Data collection sheet 
1. Study number: ____________________________________________________________________ 
2. Area/Town/City/Country:                                        
Where living currently_________________________________________________________________ 
Where lived most of his/her life__________________________________________________________ 
3. Occupation(s) - (list all dominant/major occupations or environment exposure - including radiation, 
petroleum products, pesticides/herbicides, cytotoxic, etc): _________________________________ 
             
             
4. Gender: Male □   Female □                                
5. Patient Ethnic Origin:     
African □ Asian □  White □    Coloured (mixed race)  □ Other □ (Specify_______)  
6. Date of birth:____________ Age at diagnosis_______            
7. Date of diagnostic biopsy:______________________           
8. Site of diagnostic biopsy:_______________________   
9. Duration of lymphadenopathy:___________________    
10. Histology (morphology, immunochemistry, subtypes of DLBCL, conclusion)____________________ 
        
 _________________________________________          
11. Performance status (ECOG 0-4): 
__________________________       □ 
 
12. Systemic symptoms (mark all that apply):                                                  
Unexplained weight loss (≥10% of body wt in last 6/12)                         □  
Unexplained, persistent or recurrent fever >380C                          □  
Night sweats (drenching, last 2-4 weeks)        □ 
None of the symbols listed above         □  
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13. Extranodal sites of involvement at presentation. Only tick all sites that are affected (can use same chart 
for relapse):                    
Proven by:   Clinical disease  Biopsy   Imagingstudies                                   
Spleen (size)_______.  □   □   □ 
   
Bone marrow  ₊□  -□  □   □                   □ 
  
Liver size   □   □                   □ 
  
Brain    □   □                  □ 
  
Meninges/CSF   □   □   □ 
  
Lung    □   □   □ 
  
Stomach    □   □                   □ 
  
Testis    □   □                   □ 
  
Nose and nasal cavity  □   □                   □ 
  
Paranasal sinuses   □   □   □ 
Other     □   □                   □ 
  
____________________________________________________________________________________
______________________________________________________________________  
Specify:__________________________________________________________________________ 
 
Describe the involvement in more detail where necessary________________________________ 
 
 
14. Lymphatic sites of involvement – initial examination (mark all sites that are involved only). Can use 
same chart as for relapse. 
Nodal site   Size (cm×cm)  Biopsy  Physical examination/ 
         Imaging studies 
 Cervical lymph nodes 
 Anterior triangle   ___________  ______  _________________ 
 Posterior triangle   ___________  ______  _________________ 
 Supraclavicular    ___________  ______  _________________ 
 Submental    ___________  ______  _________________ 
 Submandibular    ___________  ______  _________________ 
 Occipital   ___________  ______  _________________ 
 Pre-auricular   ___________  ______  _________________ 
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 Post-auricular   ___________  ______  _________________ 
 Axillary lymph nodes  ___________  ______  _________________ 
 Mediastinal lymph nodes 
Upper mediastinum  ___________  ______  _________________ 
Para-tracheal   ___________  ______  _________________ 
Hilar     ___________  ______  _________________ 
Other intrathoracic nodes  ___________  ______  _________________ 
 Abdominal lymph nodes 
Para-aortic   ___________  ______  _________________ 
Iliac     ___________  ______  _________________ 
Mesenteric    ___________  ______  _________________ 
Other intra-abdominal nodes ___________  ______  _________________ 
 Inguinal lymph nodes  ___________  ______  _________________ 
 Femoral lymph nodes  ___________  ______  _________________ 
 Epitrochlear lymph nodes ___________  ______  _________________ 
 Other    ___________  ______  _________________ 
15. Disease confined to one side (i.e. localized)?    Yes □  No □ 
16. Ann Arbor Stage 
I □  II □  III □  IV □  V □ 
A □  B □  X □  E □ 
17. HIV status – Positive=P, Negative=N P □  N □  Unknown □ 
If positive, duration of seropositivity_____ or first diagnosis (i.e. HIV diagnosed simultaneously) □ 
18. Post-organ transplant      Yes □  No □ 
19. Other immune suppressive drugs     Yes □  No □ 
Details_____________________________________________________________________________ 
20. Other disorders of immune system     Yes □  No □ 
List________________________________________________________________________________ 
21. Other co-morbid disease/s (include duration and treatment 
received)_________________________________________________________________________
________________________________________________________________________________
____ 
22. Past, present or post-treatment history of TB    Yes □  No □ 
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If yes, when diagnosed (date)_________and duration of treatment received_____months. 
Site of TB__________________________________________________________________________ 
Regimen used_______________________________________________________________________ 
23. If HIV positive, was cART used     Yes □  No □ 
If yes, date of initiation of treatment_______________________________________________________ 
Currently still on treatment     Yes □  No □ 
Date treatment stopped_______________Duration______________months. 
Drugs and doses (regimen/s used)  
 ___________________________________________________________________________________
___________________________________________________________________________________ 
24. Was treatment for DLBCL given     Yes □  No □ 
25. Initial treatment regimen:  CHOP □  CHOEP □ R-CHOP □  Other □ 
 If other, specify        
___________________________________________________________________ 
26. Date of initiation of first 
treatment______________________________________________________ 
Date of completion of first treatment_____________________________________________________ 
Number of cycles of treatment received___________________________________________________ 
Were multiple treatment regimens used    Yes □  No □ 
Details of regimen and number of cycles used 
_____________________________________________________________________________________
_______________________________________________________________________________ 
27. Prophylactic treatment      Yes □  No □ 
TB   Yes □  No □;  PCP  Yes □  No□  
Intrathecal chemotherapy Yes □  No□  Number of cycles □ 
Other__________________________________________________________________________ 
28. Dose modification if HIV positive: ¼ □ 1/3 □ ½ □ ¾ □ Full dose □ 
Other____________________________________________________________________________ 
29. If initial therapy was radiotherapy, was adjuvant chemotherapy give (i.e. combined modality) 
         Yes □  No □ 
Regimen________________________________________________________________________ 
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30. If initial therapy was chemotherapy, was adjuvant radiotherapy given (i.e. combined modality) 
         Yes □  No □ 
Regimen___________________________________________________________________________ 
Details of radiotherapy (in 29 and 30) 
____________________________________________________________________________________
___________________________________________________________________________________ 
31. Response to initial treatment: Complete response □ Partial response □  No response □ 
Indeterminate (reason) _______________________________________________________________ 
Non evaluable (reason) ____________________________________________________________ 
32. Date of documented relapse or progression 
_________________________________________________ 
33. Relapse or progression documented by (mark one only):  Biopsy □  Symptoms □  Imaging studies □ 
34. Sites of relapse (use charts for initial presentation) 
35. Subsequent (i.e. salvage) therapy      Yes □  No □ 
Type of treatment and response to treatment 
____________________________________________________________________________________
____________________________________________________________________________________
_________________________________________________________________________________ 
36. Did patient receive high dose therapy with stem cell transplant at any time 
        Yes □  No □ 
If yes, type of transplant:      BMT □ PBSCT □ 
Date and details of transplant____________________________________________________________ 
37. Complications (general): 
Chemotherapy related _________________________________________________________________ 
Radiotherapy related __________________________________________________________________ 
Infection ____________________________________________________________________________ 
Other ______________________________________________________________________________ 
Late complications of the disease: 
Infertility/sterility _____________________________________________________________________ 
Second malignancy ___________________________________________________________________ 
Cardiorespiratory _____________________________________________________________________ 
Endocrine ___________________________________________________________________________ 
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Psychosocial _________________________________________________________________________ 
Other _______________________________________________________________________________ 
38. Outcome   Dead □  Alive □  Lost to follow up □ 
39. A) Date of 
death______________________________________________________________________ 
B) Cause/s of death____________________________________________________________________ 
C) Was DLBCL in remission at the time of death  Yes □  No □ 
40. Alive □ Lost to follow up □ 
Date of last observation ________________________________________________________________ 
Was DLBCL in remission at date of last observation  Yes □  No □ 
Progression free survival ________months 
41. Overall survival _________months 
42. Any other relevant information 
__________________________________________________________ 
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APPENDIX B (Blood results) 
 
Study number:_________________________________________________ 
 Initial presentation Response after treatment Follow up 
Last follow up/visit 
Hb    
 
MCV    
 
MCH/MCHC    
 
Platelets    
 
Neutrophils    
 
Lymphocytes    
 
Basophils    
 
Monocytes    
 
Eosinophils    
 
Peripheral smear    
 
Reticulocyte count    
 
RPI    
 
Corrected Ca⁺⁺     
Mg⁺⁺    
 
Phosphate    
 
Sodium    
 
Potassium    
 
Urea     
 
Creatinine     
 
Total conjugated 
bilirubin 
   
 
Unconjugated bilirubin    
 
Total protein    
 
Albumin    
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ALP    
 
GGT    
 
AST    
 
ALT    
 
HIV    
 
CD4 count    
 
Viral load    
 
Iron    
 
 Initial presentation Response after treatment Follow up Last follow up visit 
Transferrin    
 
Transferrin saturation    
 
Ferritin    
 
Red cell folate    
 
Vitamin B12    
 
LDH    
 
Uric acid    
 
B2-microglobulin    
 
INR    
 
PTT    
 
 
 
 
 
  
66 
APPENDIX C (Ethics approval letter) 
 
 
  
67 
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